Preclinical study outlines cardiovascular side effects of breast cancer drug

In the search for new approaches to treat ERBB2 (also known as HER2) positive breast cancers that have become drug-resistant, Dartmouth’s Norris Cotton Cancer Center investigator Manabu Kurokawa, PhD, led a team in discovery …

... read more at: https://medicalxpress.com/news/2016-07-preclinical-outlines-cardiovascular-side-effects.html